<DOC>
	<DOC>NCT01206777</DOC>
	<brief_summary>The purpose of this study is to assess the feasibility of a 60 minute rapid infusion rituximab protocol in the institution's outpatient infusion center.</brief_summary>
	<brief_title>Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 1889 Diagnosis of indolent or intermediate grade Bcell malignancy Patients receiving rituximabbased therapy at a dose of 375mg/m2, regardless of weight First dose given within 3 months of the second dose Infusion scheduled for outpatient administration at The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Diagnosis of aggressive lymphoma Absolute lymphocyte count &gt; 10 x 103 cells/ÂµL New York Heart Association (NYHA) classification Grade II or greater congestive heart failure Enrolled on another clinical trial Allergy to murinecontaining medications Grade III or IV hypersensitivity reaction during the initial infusion of rituximab Prisoners Pregnant women Mentally or physically unable to give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hypersensitivity Reactions</keyword>
	<keyword>B-cell malignancies</keyword>
</DOC>